Phase 2 study reports on progression-free survival for advanced melanoma patients, highlighting nelitolimod's efficacy in combination with pembrolizumab.
Figure S5 shows Kaplan-Meier curves depicting progression-free survival for patients treated with nelitolimod 2 mg or 8 mg in combination with pembrolizumab 200 mg. The figure illustrates time-to-event data for each dose group.
No takes yet. Share an insight, caveat, or question.
Ribas et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: